XML 35 R20.htm IDEA: XBRL DOCUMENT
v3.24.1

STOCK-BASED COMPENSATION | 12 Months Ended
--- | ---
Feb. 03, 2024
STOCK-BASED COMPENSATION |
STOCK-BASED COMPENSATION |
11. | STOCK-BASED COMPENSATION
​ The Company recognizes compensation expense for all share-based payments granted. The Company recognizes share-based compensation expense, net of an estimated forfeiture rate, over the requisite service period of the award based on the fair value at the date of the grant. ​ The Company grants options for common shares (“stock options”) to employees under various plans at an option price equal to the fair market value of the underlying shares on the grant date of the award. The Company accounts for stock options under the fair value recognition provisions. Stock options typically expire 10 years from the date of grant. Stock options vest between one and four years from the date of grant. ​ In addition to the stock options described above, the Company awards restricted stock to employees and incentive shares to nonemployee directors under various plans. The restrictions on the restricted share awards generally lapse between one and four years from the date of the awards. The Company determines the fair value for restricted stock awards in an amount equal to the fair market value of the underlying shares on the grant date of the award. ​ At February 3, 2024, approximately 40 million common shares were available for future options or restricted stock grants under the 2019 Amended and Restated Long-Term Incentive Plan. Options granted reduce the shares available under the Plans at a ratio of one to one. Restricted stock grants reduce the shares available under the Plans at a ratio of 2.83 to one. ​ Equity awards granted are based on the aggregate value of the award on the grant date. This can affect the number of shares granted in a given year as equity awards. Excess tax benefits related to equity awards are recognized in the provision for income taxes. Equity awards may be approved at one of four meetings of its Board of Directors occurring shortly after the Company’s release of quarterly earnings. The 2023 primary grants were made in conjunction with the March and June meetings of the Company’s Board of Directors. ​ All awards become immediately exercisable upon certain changes of control of the Company. ​ Stock Options ​ Changes in options outstanding under the stock option plans are summarized below: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Shares |  | Weighted- |
​ | ​ | subject | ​ | average |
​ | ​ | to option | ​ | exercise |
​ |  | (in millions) |  | price |
Outstanding, year-end 2020 |  | 26.8 | ​ | $ | 26.65 | ​
Granted |  | 2.1 | ​ | $ | 35.45 | ​
Exercised |  | (7.1) | ​ | $ | 24.70 | ​
Canceled or Forfeited |  | (0.7) | ​ | $ | 28.88 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Outstanding, year-end 2021 |  | 21.1 | ​ | $ | 28.15 | ​
Granted |  | 1.2 | ​ | $ | 56.13 | ​
Exercised |  | (5.4) | ​ | $ | 26.02 | ​
Canceled or Forfeited |  | (0.3) | ​ | $ | 31.54 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Outstanding, year-end 2022 |  | 16.6 | ​ | $ | 30.81 | ​
Granted |  | 1.3 | ​ | $ | 47.23 | ​
Exercised |  | (2.4) | ​ | $ | 24.04 | ​
Canceled or Forfeited |  | (0.1) | ​ | $ | 39.45 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Outstanding, year-end 2023 |  | 15.4 | ​ | $ | 33.11 | ​
​ A summary of options outstanding, exercisable and expected to vest at February 3, 2024 follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted-average | ​ | ​ | ​ | ​ | Aggregate |
​ | ​ | ​ | ​ | remaining | ​ | Weighted-average | ​ | intrinsic |
​ |  | Number of shares |  | contractual life |  | exercise price | ​ | value |
​ |  | (in millions) |  | (in years) | ​ | ​ | ​ | ​ | (in millions) | ​
Options Outstanding |  | 15.4 |  | 4.78 | ​ | $ | 33.11 | ​ | $ | 214 | ​
Options Exercisable |  | 11.8 |  | 3.84 | ​ | $ | 30.01 | ​ | $ | 194 | ​
Options Expected to Vest |  | 3.5 |  | 7.87 | ​ | $ | 43.24 | ​ | $ | 20 | ​
​ ​ Restricted stock ​ Changes in restricted stock outstanding under the restricted stock plans are summarized below: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Restricted |  | ​ | ​ |
​ | ​ | shares | ​ | Weighted-average |
​ | ​ | outstanding | ​ | grant-date |
​ | ​ | (in millions) | ​ | fair value |
Outstanding, year-end 2020 |  | 7.8 | ​ | $ | 28.46 | ​
Granted |  | 3.9 | ​ | $ | 37.29 | ​
Lapsed |  | (4.0) | ​ | $ | 29.58 | ​
Canceled or Forfeited |  | (0.5) | ​ | $ | 31.31 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Outstanding, year-end 2021 |  | 7.2 | ​ | $ | 32.52 | ​
Granted |  | 3.0 | ​ | $ | 50.50 | ​
Lapsed |  | (4.0) | ​ | $ | 32.16 | ​
Canceled or Forfeited |  | (0.4) | ​ | $ | 38.32 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Outstanding, year-end 2022 |  | 5.8 | ​ | $ | 41.76 | ​
Granted |  | 3.5 | ​ | $ | 47.06 | ​
Lapsed |  | (3.1) | ​ | $ | 40.37 | ​
Canceled or Forfeited |  | (0.3) | ​ | $ | 45.32 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Outstanding, year-end 2023 |  | 5.9 | ​ | $ | 45.49 | ​
​ The weighted-average grant date fair value of stock options granted during 2023, 2022 and 2021 was $15.17, $15.91 and $8.54, respectively. The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model, based on the assumptions shown in the table below. The Black-Scholes model utilizes accounting judgment and financial estimates, including the term option holders are expected to retain their stock options before exercising them, the volatility of the Company’s share price over that expected term, the dividend yield over the term and the number of awards expected to be forfeited before they vest. Using alternative assumptions in the calculation of fair value would produce fair values for stock option grants that could be different than those used to record stock-based compensation expense in the Consolidated Statements of Operations. The decrease in the fair value of the stock options granted during 2023, compared to 2022, resulted primarily from decreases in the Company’s share price, partially offset by an increase in the weighted-average risk-free interest rate. The increase in the fair value of the stock options granted during 2022, compared to 2021, resulted primarily from increases in the Company’s share price, the weighted-average expected volatility, and an increase in the weighted-average risk-free interest rate. ​ The following table reflects the weighted-average assumptions used for grants awarded to option holders: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2023 |  | 2022 |  | 2021 |
Weighted average expected volatility |  | 31.14 | % | 30.47 | % | 28.52 | %
Weighted average risk-free interest rate |  | 4.09 | % | 2.09 | % | 1.21 | %
Expected dividend yield |  | 2.11 | % | 1.82 | % | 2.00 | %
Expected term (based on historical results) |  | 7.1 | years | 7.2 | years | 7.2 | years
​ The weighted-average risk-free interest rate was based on the yield of a treasury note as of the grant date, continuously compounded, which matures at a date that approximates the expected term of the options. The dividend yield was based on our history and expectation of dividend payouts. Expected volatility was determined based upon historical stock volatilities; however, implied volatility was also considered. Expected term was determined based upon historical exercise and cancellation experience. ​ Total stock compensation recognized in 2023, 2022 and 2021 was $172, $190 and $203, respectively. Stock option compensation recognized in 2023, 2022 and 2021 was $17, $19 and $20, respectively. Restricted shares compensation recognized in 2023, 2022 and 2021 was $155, $171 and $183, respectively. ​ The total intrinsic value of stock options exercised was $55, $159 and $121 in 2023, 2022 and 2021, respectively. The total amount of cash received in 2023 by the Company from the exercise of stock options granted under share-based payment arrangements was $50. As of February 3, 2024, there was $212 of total unrecognized compensation expense remaining related to non-vested share-based compensation arrangements granted under the Plans. This cost is expected to be recognized over a weighted-average period of approximately two years. The total fair value of options that vested was $16, $19 and $20 in 2023, 2022 and 2021, respectively. ​ Shares issued as a result of stock option exercises may be newly issued shares or reissued treasury shares. Proceeds received from the exercise of options, and the related tax benefit, may be utilized to repurchase the Company’s common shares under a stock repurchase program adopted by the Company’s Board of Directors. During 2023, the Company repurchased approximately one million common shares in such a manner.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration